LPTX
Leap Therapeutics, Inc.
2.83
USD
This page is just a preview of the data found in TrendSpider’s full version
Leap Therapeutics, Inc. stock is up 82.58% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.
Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
